Abstract/References
Population analysis of oseltamivir-resistant variants for the rapid prediction of drug susceptibility by real-time reverse transcription polymerase chain reaction
Masatoki Sato, Koichi Hashimoto, Mitsuaki Hosoya
Author information
- Masatoki Sato
Department of Pediatrics, Fukushima Medical University - Koichi Hashimoto
Department of Pediatrics, Fukushima Medical University - Mitsuaki Hosoya
Department of Pediatrics, Fukushima Medical University
Abstract
This study investigated whether quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), using specific probes composed of locked nucleic acids (LNA/qRT-PCR), designed to evaluate H1N1 pdm09 H275Y, H3N2 E119V and R292K variant populations, could replace a neuraminidase (NA) inhibition assay to determine the 50% inhibitory concentration (IC50) of NA activity.
For H1N1 pdm09, when the H275Y variant RNA load was 50% or 70% and the infective H275Y variant load was 40% or 70%, the IC50 were >10- and 100-fold higher, respectively, than that of the wild-type (WT) strain. For H3N2, when the E119V RNA load and infective E119V variant load were >90% and >60%, respectively, the IC50 of the mixed sample was >10-fold higher than that of the WT strain. The variant-mixed samples with a 70% or 80% R292K variant RNA load and a 60% or 70% infective R292K variant load exhibited >10- and 100-fold decreased susceptibility, respectively, compared with that of the WT. A positive correlation between the variant RNA load and infective variant load populations was observed.
The LNA/qRT-PCR method can be used to improve the treatment and management of patients during antiviral therapy for influenza virus infection.
References
- Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012:application of the WHO antiviral working group criteria. Influenza Other Respir Viruses, 8:258-265, 2014.
- Storms AD, Gubareva LV, Su S, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis, 18:308-311, 2012.
- Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A (H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill, 19:20666, 2014.
- Word Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses:neuraminidase inhibitor (NAI). Available at: https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza/neuraminidase-inhibitor. Accessed 16 March 2022.
- McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother, 47:2264-2272, 2003.
- Sato M, Honzumi K, Sato T, et al. Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction. J Clin Virol, 68:97-103, 2015.
- van der Vries E, Jonges M, Herfst S, et al. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J Clin Virol, 47:34-37, 2010.
- Matrosovich M, Matrosovich T, Garten W, Klenk HD. New low-viscosity overlay medium for viral plaque assays. Virol J, 3:63, 2006.
- Sato M, Honzumi K, Sato T, et al. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir. Pediatr Infect Dis J, 33:e168-e172, 2014.
- Sato M, Ito M, Suzuki S, et al. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants. Antimicrob. Agents Chemother, 59:1643-1649, 2015.
- Deyde VM, Okomo-Adhiambo M, Sheu TG, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res, 81:16-24, 2009.
Figures (5)




